Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 17, 2023 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition beviljas Orphan Drug Designation av FDA för golexanolon

STOCKHOLM, SVERIGE 17 januari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har beviljats orphan drug designation av den amerikanska...
January 17, 2023 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition is granted Orphan Drug Designation by the FDA for golexanolone

STOCKHOLM, SWEDEN – January 17, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has been granted Orphan Drug Designation by the...
January 12, 2023 05:39 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Aprea Therapeutics doserar första patienten i klinisk fas 1/2a-studie av ATRN-119

STOCKHOLM, SVERIGE 12 januari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Aprea Therapeutics har doserat den första patienten i bolagets kliniska fas...
January 12, 2023 05:39 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Aprea Therapeutics doses the first patient in a clinical phase 1/2a study of ATRN-119

STOCKHOLM, SWEDEN, January 12, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has dosed the first patient in a clinical phase 1/2a...
January 04, 2023 10:55 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag OssDsign publicerar patientrapport från TOP FUSION-studien i vetenskaplig tidskrift

STOCKHOLM, SVERIGE 4 januari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget OssDsign har publicerat en första patientrapport efter att en patient stelopererats...
January 04, 2023 10:55 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company OssDsign has published a case report from the TOP FUSION study in a scientific journal

STOCKHOLM, SWEDEN, January 4, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has published the first case report on a patient that underwent...
January 03, 2023 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition presenterar data som visar effekt av golexanolon i en preklinisk modell av Parkinsons sjukdom

STOCKHOLM, SVERIGE 3 januari 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har presenterat lovande prekliniska data för bolagets längst...
January 03, 2023 02:45 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition presents preclinical data showing effect of golexanolone in a Parkinson’s disease model

STOCKHOLM, SWEDEN – January 3, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented promising preclinical data of the...
December 27, 2022 07:03 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Dilafor har slutfört rekryteringen till en förlängningsstudie med tafoxiparin

STOCKHOLM, SVERIGE 27 december 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Dilafor har rekryterat den sista deltagaren till en förlängning av den kliniska fas...
December 27, 2022 07:03 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Dilafor has completed recruitment to an extension study of tafoxiparin

STOCKHOLM, SWEDEN – December 27, 2022. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has enrolled the last patient to an extension of the...